EV-derived miRNAs that could be used as biomarkers of prognosis or drug resistance include the exosome-derived miR-451, which induces Th17 differentiation by increasing mammalian target of rapamycin (mTOR) activity, and miR-493, whose expression correlates with paclitaxel resistance in human GC cell lines [102,103]. The gene discussed is MTOR; the disease is gastric cancer.